Format

Send to

Choose Destination
J Infect. 2014 Mar;68(3):252-8. doi: 10.1016/j.jinf.2013.09.033. Epub 2013 Nov 16.

Efficacy of IP-10 as a biomarker for monitoring tuberculosis treatment.

Author information

1
Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
2
Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea.
3
Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: mdkang@yuhs.ac.

Abstract

OBJECTIVES:

IP-10 has been proposed as a promising alternative marker for the diagnosis of tuberculosis (TB).

METHODS:

In this exploratory study, we assessed the levels of serum IP-10 and TB antigen-dependent IP-10 at the time of diagnosis and after completing treatment in 32 patients with active TB.

RESULTS:

Significant changes in concentration between the time of diagnosis and the completion of therapy were observed for serum IP-10 (P < 0.001; median: 140.4 and 105.7 pg/ml, respectively) and TB antigen-dependent IP-10 (P = 0.002; median: 20,000 and 13,720 pg/ml, respectively). The proportion of TB antigen-dependent IP-10 responders did not change significantly between baseline and the completion of therapy (P = 0.35), whereas the proportion of serum IP-10 responders was significantly different (P = 0.001).

CONCLUSIONS:

Serum IP-10 and TB antigen-dependent IP-10 responses to QFT-GIT antigens might be a useful biomarker for monitoring the efficacy of therapy in patients with active TB.

KEYWORDS:

IP-10; Monitoring; Tuberculosis

PMID:
24247066
DOI:
10.1016/j.jinf.2013.09.033
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center